Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044

Cells

Elspeth Bruford¹  on behalf of the HUGO Gene Nomenclature Committee (HGNC)² 

[1] Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge CB2 0PT, UK;HUGO Gene Nomenclature Committee, EMBL-EBI, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton CB10 1SD, UK;

关键词: gene nomenclature;    HGNC;    fragile X syndrome;    FMR1;    FRAXA;   

DOI  :  10.3390/cells11121937

来源: DOAJ

【 摘 要 】

This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term “retardation” from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network.

【 授权许可】

Unknown